Clinical Trial Update: A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Efruxifermin for nonalcoholic steatohepatitis (NASH) has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• efruxifermin (efruxifermin)

Snippet

Sponsor: Akero Therapeutics, Inc | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-08-04